Ocuphire Pharma Investor Day Presentation Deck
P
81
VEGA-1: Demographics and Baseline Characteristics
Treatment and Placebo Arms were Balanced in the VEGA-1 Phase 2 Clinical Trial
Age (years): Median (Range)
Sex: Male n (%)
Female n (%)
Race: White n (%)
Other* n (%)
Dark Iris Color: n (%)
Light Iris Color: n (%)
Photopic DCNVA Mean Letters read-
Binocular (Snellen Equiv.)
70 letters = 20/20
Photopic BCDVA Mean Letters read-
Binocular (Snellen Equiv.)
55 letters = 20/20
Photopic Pupil Diameter Mean (mm)
Mesopic Pupil Diameter Mean (mm)
Placebo
Alone
N=43
52
(42-62)
15 (35%)
28 (65%)
37 (86%)
6 (14%)
18 (42%)
25 (58%)
46
(20/63)
62
(20/15)
4.3
5.1
Nyxol
Alone
N=30
54
(41-60)
7 (23%)
23 (77%)
26 (87%)
1 (3%)
12 (40%)
18 (60%)
45
(20/63)
61
(20/15)
4.5
5.0
LDP
Alone
N=31
52
(44-64)
13 (42%)
18 (58%)
28 (90%)
3 (10%)
12 (39%)
19 (61%)
48
(20/63)
60
(20/15)
4.3
5.0
Source: VEGA-1 TLR Table 14.1.2.2 Demographics and Baseline Characteristics (PP Population). Snellen Conversion Chart.
Nyxol+LDP
Combo
N=43
53
(43-63)
5 (12%)
38 (88%)
40 (93%)
3 (7%)
18 (42%)
25.1 (58%)
46
(20/63)
61
(20/15)
4.3
5.1
Total
N=147
53
(41-64)
40 (27%)
107 (73%)
131 (89%)
15 (11%)
60 (41%)
87 (59%)
46
(20/63)
61
(20/15)
4.3
5.1
Ocuphire
PHARMAView entire presentation